Captor Therapeutics Spółka Akcyjna financials
Captor Therapeutics Spółka Akcyjna
259400JHH1S2I2S4O735 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | PLN 9.2M | PLN 4.0M |
| Cost of sales | PLN 2.1M | PLN 741.0K |
| Gross profit | PLN 7.1M | PLN 3.2M |
| Other income | PLN 2.3M | PLN 2.7M |
| Administrative expenses | PLN 19.6M | PLN 19.5M |
| Operating profit (EBIT) | -PLN 38.4M | -PLN 31.7M |
| Finance costs | PLN 657.0K | PLN 863.0K |
| Profit before tax | -PLN 35.9M | -PLN 32.6M |
| Profit for the year | -PLN 35.9M | -PLN 32.6M |
| — attributable to owners | -PLN 35.9M | -PLN 32.6M |
| Total comprehensive income | -PLN 35.9M | -PLN 32.5M |
| Per share | ||
| Basic EPS | PLN -8610.00 | PLN -7890.00 |
| Diluted EPS | PLN -8240.00 | PLN -7480.00 |
| Free cash flow / share | PLN -5472.83 | PLN -7712.86 |
| Cash flow statement | ||
| Net cash from operating activities | -PLN 22.9M | -PLN 28.5M |
| Net cash from investing activities | -PLN 17.6M | -PLN 5.1M |
| Net cash from financing activities | -PLN 6.3M | PLN 140.9M |
| Repayments of borrowings | PLN 0 | PLN 209.0K |
| Lease liability payments | PLN 5.8M | PLN 6.7M |
| Net change in cash | -PLN 46.9M | PLN 107.3M |
| Balance sheet | ||
| Total assets | PLN 113.0M | PLN 143.5M |
| Non-current assets | PLN 11.7M | PLN 13.0M |
| Property, plant & equipment | PLN 10.7M | PLN 12.6M |
| Current assets | PLN 101.3M | PLN 130.6M |
| Trade & other receivables | PLN 9.7M | PLN 11.7M |
| Cash & equivalents | PLN 71.0M | PLN 117.9M |
| Total equity | PLN 96.3M | PLN 124.2M |
| Non-current liabilities | PLN 3.3M | PLN 3.0M |
| Lease liabilities (non-current) | PLN 3.2M | PLN 2.9M |
| Current liabilities | PLN 13.4M | PLN 16.4M |
| Lease liabilities (current) | PLN 3.7M | PLN 5.2M |
| Trade & other payables | PLN 7.8M | PLN 4.7M |
| Derived metrics | ||
| Free cash flow | -PLN 23.8M | -PLN 33.6M |
| Operating margin | -418.9% | -795.5% |
| Net margin | -391.9% | -817.2% |
| Return on equity | -37.3% | -26.2% |
| Cash conversion ratio | 0.64× | 0.87× |
| Capex coverage | -25.73× | -5.57× |
| Other reported items | ||
| Adjustments For Decrease Increase In Other Operating Receivables | PLN 150.0K | -PLN 68.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | PLN 1.5M | -PLN 9.9M |
| Adjustments For Depreciation and Amortisation Expense | PLN 7.1M | PLN 7.4M |
| Adjustments For Increase Decrease In Trade and Other Payables | PLN 3.4M | -PLN 8.8M |
| Adjustments For Provisions | -PLN 4.5M | PLN 5.5M |
| Adjustments For Reconcile Profit Loss | PLN 12.9M | PLN 4.1M |
| Adjustments For Sharebased Payments | PLN 8.0M | PLN 9.5M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -PLN 111.0K | PLN 36.0K |
| Cancellation of Treasury Shares | PLN 0 | PLN 0 |
| Comprehensive Income Attributable To Owners of Parent | -PLN 35.9M | -PLN 32.5M |
| Current Deferred Income Other Than Current Contract Liabilities | PLN 126.0K | PLN 126.0K |
| Equity and Liabilities | PLN 113.0M | PLN 143.5M |
| Finance Income | PLN 3.1M | PLN 0 |
| Increase Decrease In Cash and Cash Equivalents | -PLN 46.9M | PLN 107.3M |
| Increase Decrease Through Sharebased Payment Transactions | PLN 8.0M | PLN 9.5M |
| Inflows of Cash From Investing Activities | PLN 36.8M | PLN 0 |
| Intangible Assets Other Than Goodwill | PLN 602.0K | PLN 180.0K |
| Intangible Assets Under Development | PLN 180.0K | PLN 180.0K |
| Interest Paid Classified As Financing Activities | PLN 575.0K | PLN 409.0K |
| Interest Received Classified As Investing Activities | PLN 2.9M | PLN 0 |
| Issue of Equity | PLN 4.0K | PLN 148.2M |
| Issued Capital | PLN 417.0K | PLN 413.0K |
| Liabilities | PLN 16.7M | PLN 19.3M |
| Noncurrent Provisions For Employee Benefits | PLN 51.0K | PLN 33.0K |
| Other Adjustments For Which Cash Effects Are Investing Or Financing Cash Flow | -PLN 2.6M | PLN 409.0K |
| Other Cash Payments To Acquire Equity Or Debt Instruments of Other Entities Classified As Investing Activities | PLN 53.5M | PLN 0 |
| Other Cash Receipts From Sales of Equity Or Debt Instruments of Other Entities Classified As Investing Activities | PLN 33.9M | PLN 0 |
| Other Comprehensive Income | PLN 5.0K | PLN 42.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | PLN 5.0K | PLN 4.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | PLN 0 | PLN 38.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | PLN 5.0K | PLN 4.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | PLN 0 | PLN 38.0K |
| Other Current Financial Assets | PLN 19.9M | PLN 0 |
| Other Current Nonfinancial Assets | PLN 756.0K | PLN 906.0K |
| Other Expense By Function | PLN 58.0K | PLN 5.8M |
| Other Noncurrent Receivables | PLN 228.0K | PLN 14.0K |
| Other Reserves | PLN 175.0K | PLN 175.0K |
| Other Shortterm Provisions | PLN 1.7M | PLN 6.3M |
| Outflows of Cash From Investing Activities | PLN 54.4M | PLN 5.1M |
| Proceeds From Issuing Shares | PLN 4.0K | PLN 148.2M |
| Profit Loss From Continuing Operations | -PLN 35.9M | -PLN 32.6M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | PLN 892.0K | PLN 5.1M |
| Reserve of Exchange Differences On Translation | PLN 16.0K | PLN 11.0K |
| Reserve of Sharebased Payments | PLN 19.8M | PLN 11.8M |
| Retained Earnings | -PLN 94.1M | -PLN 58.2M |
| Revenue From Government Grants | PLN 20.6M | PLN 21.9M |
| Share Premium | PLN 170.0M | PLN 170.0M |
Every line item above is a fact tagged in Captor Therapeutics Spółka Akcyjna's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (PLN), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.